Business
Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®. Through a registered direct offering (the "offering"), an affiliate of Oramed purchased approximately 14.1 mil
About this update from Alpha Tau Medical Ltd.
[{"type":"text","content":"Oramed leverages its strategic capital markets expertise to support Alpha Tau's breakthrough cancer therapy technology","length":122,"tagName":"p","attribs":{}},{"type":"text","content":"Accelerating multiple late-stage cancer therapies including: US clinical trials across four indications, manufacturing scale-up, and commercialization efforts","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"Partnership unites two innovative therapeutic delivery pioneers – Oramed's oral drug delivery platform with Alpha Tau's precision radiation delivery technology","length":167,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, April 28, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, announced today that it has successfully closed a strategic investment in Alpha Tau Medical Ltd. (Nasdaq: DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®. Through a registered direct offering (the "offering"), an affiliate of Oramed purchased approximately 14.1 million Alpha Tau's ordinary shares, at a purchase price of $2.612 per share.","length":649,"tagName":"p"},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"image","alt":"Oramed-Logo","displaySize":"","headline":null,"caption":"Oramed-Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":231,"url":"https://media.zenfs.com/en/prnewswire.com/7d6b2b5521d21d6e8150ffa26865d576"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jz1M0AZQLR2mwbanq5L6kA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQwNztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7d6b2b5521d21d6e8150ffa26865d576","width":400,"height":231}}},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"As part of this collaboration, the parties have entered into a comprehensive three-year service agreement whereby Oramed will provide Alpha Tau with investor and shareholder outreach, business strategic guidance, and capital markets expertise. This strategic investment aligns with Oramed's growth strategy to expand its footprint in innovative therapeutic delivery technologies, enablin...